Please assess the completion status of the following clinical trial:

Trial Title: Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed, locally advanced, malignancy of the rectum; based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatment~* Stage T1-4bN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:~  * CT chest/abdomen with contrast~ * MRI pelvis with contrast~ * PET/CT of the whole-body or skull base to mid-thigh~* Subjects must have had no prior therapy for cancer of the rectum~* Members of all races and ethnic groups will be included~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)~* White blood cell count \>= 3.0 K/cu mm~* Absolute neutrophil count \>= 1.5 K/cu mm~* Platelets \>= 100 K/cu mm~* Hemoglobin \>= 8.0 g/dl (the use of transfusion or other invention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable)~* Total bilirubin =\< 1.5 X institutional upper limit of normal~* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 X institutional upper limit of normal~* Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for subjects with creatinine levels above institutional normal~* Woman of childbearing potential, a negative serum or urine pregnancy test~* Willingness to use adequate contraception for 12 months after completion of all therapy~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Subjects with AJCC 7th edition stage TxN0 and/or metastatic disease outside of pelvis (suspicious lateral pelvic lymph nodes up to and including common iliacs are allowed on the protocol)~* Prior systemic chemotherapy for rectal cancer; prior chemotherapy for another malignancy is allowable as long as it has been \> 2 years since completion of therapy for previous malignancy~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study~* Prior abdominopelvic radiation or radiation for rectal cancer~* History of other malignancy in the past 2 years except non-melanomatous skin cancer, breast ductal carcinoma in situ (DCIS) and low-risk prostate adenocarcinoma~* Medical contraindications to low anterior resection or abdominoperineal resection~* Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study~* Subjects with multiple drug allergies and/or subjects who have had an allergic reaction to any intravenous iron replacement product or a known history of hypersensitivity to ferumoxytol~* Subjects with concurrent clinical diagnosis of evidence of active iron overload defined by the following 1) ferritin \>= 250 ng/mL in men or \>= 200 ng/mL in women AND 2) transferrin saturation, the ratio of plasma iron to transferrin, expressed as percent, \>= 45%~* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol~* Patients with renal insufficiency; glomerular filtration rate (GFR) \< 60~* Adult patients who require monitored anesthesia for MRI scanning~* Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium (Gd) contrast material~* Subjects with known hepatic insufficiency or cirrhosis as determined by either a prior diagnosing physician or at review at initial consultation; these disease entities do not have formal associated lab values and are thus a clinical diagnosis by the prior aforementioned physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (ferumoxytol-enhanced MRI) (Type: EXPERIMENTAL): Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).